Association Studies of Gene Polymorphisms in Toll-Like Receptors 2 and 4 in Croatian Patients with Acute Myocardial Infarction

Scandinavian Journal of Immunology

Volumn 75, Issue 5, 2012, Pages 517-523

  Dzumhur A ^a   Zibar, L ^a   Wagner, J ^a   Simundic T ^a   Dembic Z ^b   Barbic J ^a  

^a JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD DONOR; BODY MASS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CROATIA; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE;

ADULT; AGED; ATHEROSCLEROSIS; CROATIA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84859413258     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02681.x     Document Type: Article

References (36)

1. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003;89:993-7.
2. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007;4:444-54.
3. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7.
4. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13:816-25.
5. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158-61.
6. Smirnova I, Poltorak A, Chan EK, McBride C, Beutler B. Phylogenetic variation and polymorphism at the toll-like receptor 4 locus (TLR4). Genome Biol 2000;1:Research002.
7. Xu XH, Shah PK, Faure E et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103-8.
8. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005;111:2654-61.
9. Oyama J, Blais C Jr, Liu X et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109:784-9.
10. Ferwerda B, McCall MB, Verheijen K et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 2008;14:346-52.
11. Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. New Engl J Med 2002;347:185-92.
12. Kolek MJ, Carlquist JF, Muhlestein JB et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004;148:1034-40.
13. Ameziane N, Beillat T, Verpillat P et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23:e61-4.
14. Balistreri CR, Candore G, Colonna-Romano G et al. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 2004;292:2339-40.
15. Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003;170:187-90.
16. Koch W, Hoppmann P, Pfeufer A, Schomig A, Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J 2006;27:2524-9.
17. Shishido T, Nozaki N, Takahashi H et al. Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem Biophys Res Commun 2006;345:1446-53.
18. Selejan S, Poss J, Walter F et al. Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic shock. Eur Heart J 2011; doi: 10.1093/eurheartj/ehr377. http://www.ncbi.nlm.nih.gov/pubmed/21998404.
19. Mulick AE, Soldau K, Kiosses WB, Bel TA III, Tobias PS, Curtiss K. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med 2008;205:373-83.
20. Shishido T, Nozaki N, Yamaguchi S et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-10.
21. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;68:6398-401.
22. Ogus AC, Yoldas B, Ozdemir T et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004;23:219-23.
23. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004;113:565-7.
24. Hamann L, Gomma A, Schroder NW et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med (Berl) 2005;83:478-85.
25. Labrum R, Bevan S, Sitzer M, Lorenz M, Markus HS. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007;38:1179-84.
26. Bochud PY, Hawn TR, Siddiqui MR et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008;197:253-61.
27. Park Y, Park S, Yoo E, Kim D, Shin H. Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann N Y Acad Sci 2004;1037:170-4.
28. Etokebe GE, Skjeldal F, Nilsen N et al. Toll-like receptor 2 (P631H) mutant impairs membrane internalization and is a dominant negative allele. Scand J Immunol 2010;71:369-81.
29. Ross R. Atherosclerosis - an inflammatory disease. New Engl J Med 1999;340:115-26.
30. Etokebe GE, Knezevic J, Petricevic B, Pavelic J, Vrbanec D, Dembic Z. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol Biomarkers 2009;13:729-34.
31. Chen Y, Wang J, Nie R, Zhou S. Endogenous pro-resolving and anti-inflammatory lipid mediators: the new hope of atherosclerotic diseases. Med Hypotheses 2008;71:237-40.
32. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001;276:16683-9.
33. Lee JY, Plakidas A, Lee WH et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003;44:479-86.
34. Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics 2001;19:411-20.
35. Yang J, Jiang H, Yang J et al. Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 2009;330:39-46.
36. Dasu MR, Riosvelasco AC, Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 2009;202:76-83.